Your shopping cart is currently empty

Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $30 | In Stock | In Stock | |
| 25 mg | $43 | In Stock | In Stock | |
| 50 mg | $61 | In Stock | In Stock | |
| 100 mg | $94 | In Stock | In Stock | |
| 500 mg | $263 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. |
| Targets&IC50 | COX-1:116 μM (in human whole blood), COX-2:1.1 μM COX-1 |
| In vivo | The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti- proliferative agent in the colon[2]. |
| Cell Research | Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference) |
| Synonyms | Tauxib, Nucoxia, MK-663, L-791456, Desvenlafaxine, Arcoxia |
| Molecular Weight | 358.84 |
| Formula | C18H15ClN2O2S |
| Cas No. | 202409-33-4 |
| Smiles | CC1=NC=C(C=C1)C1=NC=C(Cl)C=C1C1=CC=C(C=C1)S(C)(=O)=O |
| Relative Density. | 1.298 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 43 mg/mL (119.83 mM), Sonication is recommended. DMSO: 252 mg/mL (702.26 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.93 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.